XZP-3287 is under clinical development by Sihuan Pharmaceutical Holdings Group and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XZP-3287’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XZP-3287 (birociclib) is under development for the treatment of solid tumors including a malignant brain tumor and hormone receptor positive breast cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer). It acts by targeting cyclin-dependent kinases (CDK) 4 and 6. It is administered orally as a tablet.
Sihuan Pharmaceutical Holdings Group overview
Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical) is a pharmaceutical company that develops, manufactures, and markets prescription drugs. The company offers products in the therapeutic areas of Cardio-Cerebral Vascular, Digestive System, Anti-Infective, Metabolism, Respiratory, Neurology, and Others. It offers products under the brand names Tenedid, Tenaxin, Xiangtong, Aogan, Aohuan, Aoying, Aomeina, Ren’ao, Ashenqnuooqi, Aosaixin, and Huineng among others. The company sells its products through its distribution to network hospitals and medical institutions in Zhejiang, Guangdong, and Henan. Sihuan Pharmaceutical is headquartered in Beijing City, Beijing, China.
For a complete picture of XZP-3287’s drug-specific PTSR and LoA scores, buy the report here.